EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021

Mark A Fletcher, Derek Daigle, Mariana Siapka, Marc Baay, Germaine Hanquet, Graciela Del Carmen Morales

Frontiers in Public Health · 10.07.2024 · 12

DOI: 10.3389/fpubh.2024.1402795 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Public Health, online erschienen am 10.07.2024. Verfasst von Mark A Fletcher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Vaccines Emerging Markets, Medical Affairs, Paris, France. Hauptthemen laut MEDLINE: Pneumococcal Infections, Serogroup, Streptococcus pneumoniae, Pneumococcal Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most publications on invasive pneumococcal disease (IPD) serotype distribution are from about 20 countries (Australia, Canada, China, European Union members, Japan, New Zealand, South Korea, and USA). Here, we reviewed the literature among underrepresented countries in the Americas (AMRO), Africa (AFRO), Eastern Mediterranean (EMRO), South-East Asia (SEARO), and Western Pacific (WPRO) WHO regions.

Methods

We performed a systematic review of the most recent IPD serotype surveillance publications (from 01/01/2010 to 31/12/2021, Medline/Embase) in those WHO regions. Selection criteria were delineated by contemporality, within-country geographical scope, and number of samples. Reported serotype distributions for each country were stratified by age group, pneumococcal conjugate vaccine (PCV) serotype category (considering undifferentiated serotypes), and PCV program period (pre-PCV, intermediate, or PCVhv [higher valency PCV formulation]). Pre-PCV period pooled data estimated PCV serotype category distribution by age group across WHO regions, while for the PCVhv period, country-level dataset tables were prepared.

Results

Of 2,793 publications screened, 107 were included (58 pediatric, 11 adult, 37 all ages, and one comprising every age group). One-third of eligible countries (51/135) published serotype distribution, ranging from 30 to 43% by WHO region. Considering number of samples per WHO region, a few countries prevailed: AMRO (Brazil), AFRO (South Africa, Malawi, and Burkina Faso), and WPRO (Taiwan). In the pre-PCV period, PCV13 formulation serotypes predominated: ranging from 74 to 85% in children and 58–86% in adults in the different WHO regions. The PCVhv period represented half of the most recent IPD surveillance by countries (26/51). Undifferentiated serotypes represented >20% of IPD from most countries (34/51).

Conclusion

Ubiquity of undifferentiated serotypes among the publications could constrain estimates of PCV program impact and of serotype coverage for newer PCVhv formulations; consequently, we recommend that countries favor techniques that identify serotypes specifically and, rather than reporting PCV formulation serotype distributions, provide serotype results individually.

Systematic review registration

The protocol has been prospectively registered at PROSPERO, identifier: CRD42021278501. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278501 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal InfectionsSerogroupStreptococcus pneumoniaePneumococcal VaccinesHumansAmericasAfricaWorld Health OrganizationAsia, SoutheasternVaccines, ConjugateChildChild, PreschoolInfant

Stichwörter der Autor:innen

IPD (invasive pneumococcal disease)World Health Organizationage groupsimmunization programspneumococcal conjugate vaccinesserotypesurveillanceundifferentiated

Substanzen

Pneumococcal VaccinesVaccines, Conjugate

Autor:innen und Institutionen

  • Pfizer Vaccines Emerging Markets, Medical Affairs, Paris, France.
  • Pfizer Vaccines Emerging Markets, Medical Affairs, New York, NY, United States.
  • P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.

Förderung

  • Pfizer

Zitieren

APA

Fletcher, M. A., Daigle, D., Siapka, M., Baay, M., Hanquet, G., & Del Carmen Morales, G. (2024). Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021. Frontiers in Public Health, 12. https://doi.org/10.3389/fpubh.2024.1402795

Vancouver

Fletcher MA, Daigle D, Siapka M, Baay M, Hanquet G, Del Carmen Morales G. Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021. Frontiers in Public Health. 2024;12. doi:10.3389/fpubh.2024.1402795

BibTeX
@article{Fletcher2024,
  author = {Fletcher, Mark A and Daigle, Derek and Siapka, Mariana and Baay, Marc and Hanquet, Germaine and Del Carmen Morales, Graciela},
  title = {Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021},
  journal = {Frontiers in Public Health},
  year = {2024},
  volume = {12},
  doi = {10.3389/fpubh.2024.1402795}
}
Kostenlos starten →